Contact

All Stories

  1. Toxicité rénale des produits de contraste non iodés

    Article • Néphrologie & Thérapeutique, November 2018, Elsevier

    Dr Vincent Launay-Vacher

  2. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia

    Article • Critical Reviews in Oncology/Hematology, September 2018, Elsevier

    Dr. Luiz H Arantes Jr., Dr Vincent Launay-Vacher

  3. Anticoagulants in frail patients. Seven situations at risk

    Article • JMV-Journal de Médecine Vasculaire, September 2018, Elsevier

    Dr Vincent Launay-Vacher

  4. Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology

    Article • The Lancet Oncology, June 2018, Elsevier

    Dr Vincent Launay-Vacher

  5. Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network

    Article • Journal of Onco-Nephrology, June 2018, SAGE Publications

    Dr Vincent Launay-Vacher

  6. OUP accepted manuscript

    Article • Nephrology Dialysis Transplantation, January 2018, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher, Prof. Maurizio Gallieni

  7. Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network

    Article • Clinical Kidney Journal, October 2017, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  8. Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis

    Article • Expert Opinion on Drug Metabolism & Toxicology, February 2017, Taylor & Francis

    Dr Vincent Launay-Vacher

  9. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

    Article • American Journal of Nephrology, January 2017, Karger Publishers

    Dr Vincent Launay-Vacher, Kenar Jhaveri

  10. Renal function and venous thromboembolic diseases

    Article • Journal des Maladies Vasculaires, December 2016, Elsevier

    Dr Vincent Launay-Vacher

  11. Course of chronic kidney disease in French patients

    Article • Clinical Kidney Journal, September 2016, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  12. Renal insufficiency and cancer treatments

    Article • ESMO Open, August 2016, BMJ

    Dr Vincent Launay-Vacher

  13. Renal Dysfunction Has Statistically and Clinically Significant Deleterious Effects on Anticancer Drug Safety

    Article • Journal of Clinical Oncology, July 2016, American Society of Clinical Oncology (ASCO)

    Dr Vincent Launay-Vacher

  14. Effets rénovasculaires des antiangiogéniques

    Article • Bulletin du Cancer, July 2016, Elsevier

    Dr Vincent Launay-Vacher

  15. Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France

    Article • Supportive Care in Cancer, March 2016, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  16. Drug–drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists

    Article • Annals of Oncology, January 2016, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  17. Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network

    Article • Clinical Kidney Journal, January 2016, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  18. P-176: Direct oral anticoagulant drugs and renal function

    Article • Annales de Cardiologie et d Angéiologie, December 2015, Elsevier

    Dr Vincent Launay-Vacher

  19. Onco-Nephrology: Core Curriculum 2015

    Article • American Journal of Kidney Diseases, November 2015, Elsevier

    Dr Vincent Launay-Vacher

  20. Tolérance rénovasculaire du bévacizumab dans le cancer du sein. Valeur pronostique de l’hypertension et de la protéinurie

    Article • Bulletin du Cancer, November 2015, Elsevier

    Dr Vincent Launay-Vacher

  21. Anticancer Drugs in End-Stage Kidney Disease Patients

    Article • Seminars in Dialysis, April 2015, Wiley

    Dr Vincent Launay-Vacher

  22. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)

    Article • Annals of Oncology, March 2015, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  23. Adaptation posologique chez les patients insuffisants rénaux chroniques et évaluation de la fonction rénale : focus sur les patients de cardiologie

    Article • Annales de Cardiologie et d Angéiologie, February 2015, Elsevier

    Dr Vincent Launay-Vacher

  24. Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in postmenopausal women: a rationale for future clinical studies

    Article • Cancer Chemotherapy and Pharmacology, January 2015, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  25. Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists

    Article • Targeted Oncology, September 2014, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  26. New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment

    Article • Drugs, July 2014, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  27. Renal insufficiency, mortality, and drug management in heart transplant. Results of the CARIN study

    Article • Transplant International, June 2014, Wiley

    Dr Vincent Launay-Vacher

  28. Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients

    Article • Cancer, April 2014, Wiley

    Dr Vincent Launay-Vacher

  29. Prevalence of renal abnormalities in chronic HBV infection: The HARPE study

    Article • Liver International, March 2014, Wiley

    Dr Vincent Launay-Vacher

  30. Incidence of Nephrogenic Systemic Fibrosis in Patients Undergoing Dialysis After Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium-Based Contrast Agents

    Article • Investigative Radiology, February 2014, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

  31. Cancer and the kidney: individualizing dosage according to renal function

    Article • Annals of Oncology, October 2013, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  32. An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs

    Article • Cancer Chemotherapy and Pharmacology, September 2013, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  33. Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey

    Article • Supportive Care in Cancer, May 2013, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  34. Malaria Prophylaxis in Patients with Renal Impairment

    Article • Drug Safety, February 2013, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  35. Pulmonary Hypertension: Use of Oral Drugs in Patients with Renal Insufficiency

    Article • Clinical Drug Investigation, December 2012, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  36. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study

    Article • Annals of Oncology, October 2012, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  37. Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads

    Article • Supportive Care in Cancer, September 2012, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  38. Correspondance à propos de l’article « Rein et infection par le virus de l’immunodéficience humaine »

    Article • La Presse Médicale, September 2012, Elsevier

    Dr Vincent Launay-Vacher

  39. Importance of monitoring renal function in patients with cancer

    Article • Cancer Treatment Reviews, May 2012, Elsevier

    Dr Vincent Launay-Vacher

  40. Mise à jour des recommandations de la MASCC et de l’ESMO pour la prévention des nausées et vomissements chimio- et radio-induits: résultats de la conférence de consensus de Pérouse

    Article • ONCOLOGIE, April 2012, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  41. European society of clinical pharmacy (ESCP) glossary of scientific terms: a tool for standardizing scientific jargon

    Article • International Journal of Clinical Pharmacy, March 2012, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  42. Colony stimulating factors (CSF) biosimilars. Progress?

    Article • Targeted Oncology, January 2012, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  43. Evaluation of current practice

    Article • Anti-Cancer Drugs, October 2011, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

  44. Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma

    Article • Urologic Oncology Seminars and Original Investigations, September 2011, Elsevier

    Dr Vincent Launay-Vacher

  45. Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease

    Article • Cancer Chemotherapy and Pharmacology, August 2011, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  46. La formule aMDRD est la formule de choix pour évaluer la fonction rénale, y compris chez les patients de plus de 80ans : commentaire sur l’article de Andro et al.

    Article • La Revue de Médecine Interne, June 2011, Elsevier

    Dr Vincent Launay-Vacher

  47. MéMoPratic’ VDHA: guide de prescription pour les voies digestives hautes altérées

    Article • ONCOLOGIE, March 2011, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  48. MéMoPratic’ VDHA*: douleurs et soins de support: guide de prescription pour les voies digestives hautes altérées

    Article • Douleur et Analgésie, March 2011, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  49. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study

    Article • Nephrology Dialysis Transplantation, February 2011, Oxford University Press (OUP)

    Prof Marc Froissart, Dr Vincent Launay-Vacher

  50. Cancer and renal insufficiency results of the BIRMA study

    Article • British Journal of Cancer, November 2010, Nature

    Dr Vincent Launay-Vacher

  51. Epidemiology of Chronic Kidney Disease in Cancer Patients: Lessons From the IRMA Study Group

    Article • Seminars in Nephrology, November 2010, Elsevier

    Dr Vincent Launay-Vacher

  52. Toxicité rénale des médicaments

    Article • Néphrologie & Thérapeutique, February 2010, Elsevier

    Dr Vincent Launay-Vacher

  53. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: Results of the FINEST study

    Article • European Journal of Radiology, February 2010, Elsevier

    Dr Vincent Launay-Vacher

  54. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients

    Article • Annals of Oncology, January 2010, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  55. Drug Management of Prostate Cancer: Prevalence and Consequences of Renal Insufficiency

    Article • Clinical Genitourinary Cancer, October 2009, Elsevier

    Dr Vincent Launay-Vacher

  56. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): The TRY study

    Article • Liver Transplantation, September 2009, Wiley

    Dr Vincent Launay-Vacher

  57. Ostéonécrose mandibulaire et bisphosphonates : état actuel et perspectives

    Article • La Revue de Médecine Interne, August 2009, Elsevier

    Dr Vincent Launay-Vacher

  58. Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study

    Article • Critical Reviews in Oncology/Hematology, May 2009, Elsevier

    Dr Vincent Launay-Vacher

  59. Prise en charge des effets dermatologiques sous erlotinib. Résultats de l’étude PRECEDE

    Article • Cancer/Radiothérapie, April 2009, Elsevier

    Dr Vincent Launay-Vacher

  60. Renal Safety of Gadolinium-based Contrast Media in Patients with Chronic Renal Insufficiency

    Article • Radiology, March 2009, Radiological Society of North America (RSNA)

    Dr Vincent Launay-Vacher

  61. Hypertension and proteinuria: a class-effect of antiangiogenic therapies

    Article • Anti-Cancer Drugs, January 2009, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

  62. Lung Cancer and Renal Insufficiency: Prevalence and Anticancer Drug Issues

    Article • Lung, October 2008, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  63. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?

    Article • Annals of Oncology, October 2008, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  64. Cetuximab Pharmacokinetics in End-Stage Kidney Disease Under Hemodialysis

    Article • Journal of Clinical Oncology, September 2008, American Society of Clinical Oncology (ASCO)

    Dr Vincent Launay-Vacher

  65. Prescrire les bisphosphonates IV pour la prise en charge des métastases osseuses chez le patient insuffisant rénal

    Article • Progrès en Urologie - FMC, September 2008, Elsevier

    Dr Vincent Launay-Vacher

  66. GPR-Antibactériens

    Article • Le Pharmacien Hospitalier, September 2008, Elsevier

    Dr Vincent Launay-Vacher

  67. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

    Article • Breast Cancer Research and Treatment, August 2008, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  68. Comment on: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study: reply

    Article • Rheumatology, April 2008, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  69. Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer

    Article • Clinical Kidney Journal, April 2008, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  70. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

    Article • Cancer Chemotherapy and Pharmacology, March 2008, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  71. Pharmacocinétique de l'amprénavir chez deux patients infectés par le VIH-1 et présentant une insuffisance rénale sévère et terminale

    Article • Médecine et Maladies Infectieuses, December 2007, Elsevier

    Dr Vincent Launay-Vacher

  72. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study

    Article • Rheumatology, November 2007, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  73. Letter

    Article • International Journal of Gynecological Cancer, November 2007, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

  74. Vaccination and chronic kidney disease

    Article • Nephrology Dialysis Transplantation, October 2007, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  75. Antiretroviral Drug Dosing Errors in HIV-Infected Patients Undergoing Hemodialysis

    Article • Clinical Infectious Diseases, September 2007, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  76. 1303 POSTER Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology (SIOG) clinical practice recommendations.

    Article • European Journal of Cancer Supplements, September 2007, Elsevier

    Dr Vincent Launay-Vacher

  77. 1300 POSTER Chemotherapy in elderly patients with renal Insufficiency. Recommendations of the International Society of Geriatric Oncology (SIOG)

    Article • European Journal of Cancer Supplements, September 2007, Elsevier

    Dr Vincent Launay-Vacher

  78. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations

    Article • Annals of Oncology, August 2007, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  79. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency

    Article • European Journal of Cancer, January 2007, Elsevier

    Dr Vincent Launay-Vacher

  80. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

    Article • Cancer, January 2007, Wiley

    Dr Vincent Launay-Vacher

  81. Néphrotoxicité des médicaments: veille bibliographique janvier 2003–décembre 2005

    Article • Néphrologie & Thérapeutique, November 2006, Elsevier

    Dr Vincent Launay-Vacher

  82. Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure

    Article • Nephrology Dialysis Transplantation, September 2006, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  83. Gemcitabine-induced thrombotic microangiopathy: a systematic review

    Article • Nephrology Dialysis Transplantation, September 2006, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  84. Renal Tubular Drug Transporters

    Article • Nephron Physiology, June 2006, Karger Publishers

    Dr Vincent Launay-Vacher

  85. Renal insufficiency in cancer patients: Prevalence and implications on anticancer drugs management. Final results of the “IRMA” study

    Article • Bone, March 2006, Elsevier

    Dr Vincent Launay-Vacher

  86. Abnormal blood pressure circadian rhythm: A target organ damage?

    Article • International Journal of Cardiology, March 2006, Elsevier

    Dr Vincent Launay-Vacher

  87. Prescription des statines en cas d’insuffisance rénale

    Article • La Presse Médicale, February 2006, Elsevier

    Dr Vincent Launay-Vacher

  88. Drug-induced glomerulopathies

    Article • Expert Opinion on Drug Safety, December 2005, Informa Healthcare

    Dr Vincent Launay-Vacher

  89. Thrombocytopenia induced by nicotinamide in hemodialysis patients

    Article • Kidney International, December 2005, Elsevier

    Dr Vincent Launay-Vacher

  90. Néphrotoxicité des médicaments : veille bibliographique janvier 2003–décembre 2004

    Article • Néphrologie & Thérapeutique, November 2005, Elsevier

    Dr Vincent Launay-Vacher

  91. Hepatitis C infection and proteinuria

    Article • Kidney International, November 2005, Elsevier

    Dr Vincent Launay-Vacher

  92. Hepatitis C infection

    Article • Kidney International, November 2005, Elsevier

    Dr Vincent Launay-Vacher

  93. Drug-induced diabetes mellitus

    Article • Expert Opinion on Drug Safety, October 2005, Informa Healthcare

    Dr Vincent Launay-Vacher

  94. Immunosuppressive and calcimimetic drug-drug interactions

    Article • Kidney International, October 2005, Elsevier

    Dr Vincent Launay-Vacher

  95. Immunosuppressive and calcimimetic drug-drug interactions

    Article • Kidney International, October 2005, Elsevier

    Dr Vincent Launay-Vacher

  96. Viral Load and HIV-Associated Nephropathy

    Article • New England Journal of Medicine, September 2005, New England Journal of Medicine (NEJM/MMS)

    Dr Vincent Launay-Vacher

  97. FHD: An Index to Evaluate Drug Elimination by Hemodialysis

    Article • American Journal of Nephrology, August 2005, Karger Publishers

    Dr Vincent Launay-Vacher

  98. E.F.P. – European Fellowship for Pharmacists Promoting Clinical Pharmacy in Europe

    Article • Pharmacy World & Science, August 2005, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  99. Thalidomide for the nephrologist

    Article • Nephrology Dialysis Transplantation, July 2005, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  100. Antiretroviral drugs and the kidney: Further precisions

    Article • Kidney International, July 2005, Elsevier

    Dr Vincent Launay-Vacher

  101. Antiretroviral drugs and the kidney: Further precisions

    Article • Kidney International, July 2005, Elsevier

    Dr Vincent Launay-Vacher

  102. Néphropathie induite par les produits de contraste iodés, l’épuration extrarénale est-elle efficace en prevention ?

    Article • La Presse Médicale, June 2005, Elsevier

    Dr Vincent Launay-Vacher

  103. Statins' dosage in patients with renal failure and cyclosporine drug–drug interactions in transplant recipient patients

    Article • International Journal of Cardiology, May 2005, Elsevier

    Dr Vincent Launay-Vacher

  104. Toxicité rénale des anticancéreux

    Article • Néphrologie & Thérapeutique, May 2005, Elsevier

    Dr Vincent Launay-Vacher

  105. Antiviral Drug-Induced Nephrotoxicity

    Article • American Journal of Kidney Diseases, May 2005, Elsevier

    Dr Vincent Launay-Vacher

  106. Fanconi syndrome associated with didanosine therapy

    Article • AIDS, May 2005, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

  107. Atazanavir: a novel inhibitor of HIV-protease in haemodialysis

    Article • Nephrology Dialysis Transplantation, March 2005, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  108. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study

    Article • Nephrology Dialysis Transplantation, March 2005, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  109. Renal tubular transporters and antiviral drugs: an update

    Article • AIDS, March 2005, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

  110. Treatment of pain in patients with renal insufficiency: The World Health Organization three-step ladder adapted

    Article • Journal of Pain, March 2005, Elsevier

    Dr Vincent Launay-Vacher

  111. Pharmacokinetic Considerations in the Treatment of Tuberculosis in Patients with Renal Failure

    Article • Clinical Pharmacokinetics, January 2005, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  112. Antiretroviral Drugs and The Kidney: Dosage Adjustment and Renal Tolerance

    Article • Current Pharmaceutical Design, December 2004, Bentham Science Publishers

    Dr Vincent Launay-Vacher

  113. Why is a shrunken bladder and a nephrotic kidney an expression of the same disease?

    Article • Nephrology Dialysis Transplantation, December 2004, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  114. Reply from the Authors

    Article • Kidney International, December 2004, Elsevier

    Dr Vincent Launay-Vacher

  115. Anemia and Diabetes

    Article • American Journal of Nephrology, December 2004, Karger Publishers

    Dr Vincent Launay-Vacher

  116. Using the right MDRD equation

    Article • Kidney International, November 2004, Elsevier

    Dr Vincent Launay-Vacher

  117. Doxycycline, gastrointestinal bleeding, and thrombotic microangiopathy

    Article • American Journal of Hematology, October 2004, Wiley

    Dr Vincent Launay-Vacher

  118. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies

    Article • Kidney International, September 2004, Elsevier

    Dr Vincent Launay-Vacher

  119. Antiretroviral and immunosuppressive drug-drug interactions: An update

    Article • Kidney International, August 2004, Elsevier

    Dr Vincent Launay-Vacher

  120. Renal safety of tenofovir in HIV treatment-experienced patients

    Article • AIDS, April 2004, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

  121. Nelfinavir and felodipine: a cytochrome P450 3A4?mediated drug interaction

    Article • Clinical Pharmacology & Therapeutics, April 2004, Nature

    Dr Vincent Launay-Vacher

  122. Lymphadenopathy and proteinuria

    Article • Nephrology Dialysis Transplantation, February 2004, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  123. Epidemiology of microscopic polyarteritis: A 16-year study

    Article • Kidney International, February 2004, Elsevier

    Dr Vincent Launay-Vacher

  124. Ear and kidney syndromes: Molecular versus clinical approach

    Article • Kidney International, February 2004, Elsevier

    Dr Vincent Launay-Vacher

  125. Oculorenal manifestations in systemic autoimmune diseases

    Article • American Journal of Kidney Diseases, February 2004, Elsevier

    Dr Vincent Launay-Vacher

  126. Topiramate-induced renal tubular acidosis

    Article • The American Journal of Medicine, February 2004, Elsevier

    Dr Vincent Launay-Vacher

  127. Hemodialysis and ADAMTS-13

    Article • Blood Purification, January 2004, Karger Publishers

    Dr Vincent Launay-Vacher

  128. Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysis

    Article • Kidney International, December 2003, Elsevier

    Dr Vincent Launay-Vacher

  129. Dosing guidelines for fluconazole in patients with renal failure

    Article • Nephrology Dialysis Transplantation, November 2003, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  130. Pharmacokinetics of tenofovir in haemodialysis

    Article • Nephrology Dialysis Transplantation, September 2003, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  131. Medication misuse in hospitalized patients with renal impairment

    Article • International Journal for Quality in Health Care, August 2003, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  132. Assessing residents' prescribing behavior in renal impairment

    Article • International Journal for Quality in Health Care, May 2003, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  133. Drug-induced Fanconi's syndrome

    Article • American Journal of Kidney Diseases, February 2003, Elsevier

    Dr Vincent Launay-Vacher

  134. Eye and Kidney: From Clinical Findings to Genetic Explanations

    Article • Journal of the American Society of Nephrology, February 2003, American Society of Nephrology

    Dr Vincent Launay-Vacher

  135. Fanconi and Inappropriate Secretion of Antidiuretic Hormone Syndromes Secondary to Venlafaxine Therapy

    Article • October 2002, Karger Publishers

    Dr Vincent Launay-Vacher

  136. Pharmacokinetics of Tramadol in a Hemodialysis Patient

    Article • September 2002, Karger Publishers

    Dr Vincent Launay-Vacher

  137. Lymphopenia in Wegener’s Granulomatosis

    Article • September 2002, Karger Publishers

    Dr Vincent Launay-Vacher

  138. Retroperitoneal fibrosis due to Wegener’s granulomatosis: a misdiagnosis as tuberculosis

    Article • The American Journal of Medicine, August 2002, Elsevier

    Dr Vincent Launay-Vacher

  139. Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: Case report and review of the literature

    Article • Clinical Pharmacology & Therapeutics, June 2002, Nature

    Dr Vincent Launay-Vacher

  140. Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient

    Article • Nephrology Dialysis Transplantation, March 2002, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  141. Article • Critical Care, January 2002, Springer Science + Business Media

    Dr Vincent Launay-Vacher

  142. Gabapentin neurotoxicity in a chronic haemodialysis patient

    Article • Nephrology Dialysis Transplantation, October 2001, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  143. An appraisal of antiretroviral drugs in hemodialysis

    Article • Kidney International, September 2001, Elsevier

    Dr Vincent Launay-Vacher

  144. Pharmacokinetics of Abacavir in HIV-1-Infected Patients with Impaired Renal Function

    Article • August 2001, Karger Publishers

    Dr Vincent Launay-Vacher

  145. Effect of N-acetylcysteine on serum creatinine level

    Article • Nephrology Dialysis Transplantation, July 2001, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  146. Neurotoxicity of Valacyclovir in Peritoneal Dialysis: A Pharmacokinetic Study

    Article • American Journal of Nephrology, May 2001, Karger Publishers

    Dr Vincent Launay-Vacher

  147. Severe methotrexate intoxication in a haemodialysis patient treated for rheumatoid arthritis

    Article • Nephrology Dialysis Transplantation, May 2001, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  148. Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis

    Article • Nephrology Dialysis Transplantation, March 2001, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  149. ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis

    Article • AIDS, March 2001, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

  150. Pharmacokinetics of Ritonavir and Saquinavir in a Haemodialysis Patient

    Article • February 2001, Karger Publishers

    Dr Vincent Launay-Vacher

  151. Tolerance and Pharmacokinetics of High Doses of Interferon-alpha-2a in a Hemodialysis Patient

    Article • January 2001, Karger Publishers

    Dr Vincent Launay-Vacher

  152. Pharmacokinetic of nevirapine in haemodialysis

    Article • Nephrology Dialysis Transplantation, January 2001, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  153. Dosage of Lamivudine in a Haemodialysis Patient

    Article • December 2000, Karger Publishers

    Dr Vincent Launay-Vacher

  154. Indinavir pharmacokinetics in haemodialysis

    Article • Nephrology Dialysis Transplantation, July 2000, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  155. Baclofen unerotoxicity in a chronic haemodialysis patient

    Article • Nephrology Dialysis Transplantation, May 2000, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

  156. Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis

    Article • AIDS, March 2000, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

  157. Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency

    Article • AIDS, October 1999, Wolters Kluwer Health

    Dr Vincent Launay-Vacher